Johns Hopkins Bloomberg School of Public Health

Study: FDA Regulation of Abortion Drug Mifepristone from 2011 to 2023 Shaped by Evidence and Caution

Review of hundreds of internal FDA documents obtained under FOIA finds FDA generally followed cautious and evidence-based ...